Shire : Form 8.5 (EPT/NON-RI)

October 01, 2014 at 08:41 am EDT

FORM 8.5 (EPT/NON-RI)

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY ("RI") STATUS (OR WHERE RI STATUS IS NOT APPLICABLE)

Rule 8.5 of the Takeover Code (the "Code")

1. KEY INFORMATION

(a) Name of exempt principal trader:	(GS) GOLDMAN, SACHS & CO.
(b) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree	SHIRE PLC
(c) Name of the party to the offer with which exempt principal trader is connected:	SHIRE PLC
(d) Date position held/dealing undertaken:	30 September 2014
(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?	NO

2. POSITIONS OF THE EXEMPT PRINCIPAL TRADER

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:	5p ordinary and ADRs
	Interests		Short positions
	Number	%	Number	%
(1) Relevant securities owned and/or controlled:	715,914	0.12	218,970	0.03
(2) Derivatives (other than options):	0	0.00	184,320	0.03
(3) Options and agreements to purchase/sell:	0	0.00	0	0.00
TOTAL:	715,914	0.12	403,290	0.06

All interests and all short positions should be disclosed.

Details of any open derivative or option positions, or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors' and other executive options)

Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

3. DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER

(a) Purchases and sales

Class of relevant security	Purchase/sale	Number of securities	Price per unit
ADR / (1.00 : 3.00)	Purchase	100 (300)	258.2900 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	258.3200 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	258.3400 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	258.3600 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	258.3900 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	258.4000 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	258.4000 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	258.4100 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	258.4100 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	258.4100 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	258.4100 USD
ADR / (1.00 : 3.00)	Purchase	60 (180)	258.4400 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	258.4900 USD
ADR / (1.00 : 3.00)	Purchase	50 (150)	258.4900 USD
ADR / (1.00 : 3.00)	Purchase	50 (150)	258.4900 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	258.4900 USD
ADR / (1.00 : 3.00)	Purchase	53 (159)	258.5500 USD
ADR / (1.00 : 3.00)	Purchase	10 (30)	258.5500 USD
ADR / (1.00 : 3.00)	Purchase	90 (270)	258.5600 USD
ADR / (1.00 : 3.00)	Purchase	47 (141)	258.5700 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	258.8800 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	258.9000 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	258.9600 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	258.9700 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	258.9900 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	258.9900 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	258.9900 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.0700 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.0900 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.1400 USD
ADR / (1.00 : 3.00)	Purchase	76 (228)	259.1800 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.1900 USD
ADR / (1.00 : 3.00)	Purchase	15 (45)	259.3300 USD
ADR / (1.00 : 3.00)	Purchase	85 (255)	259.3300 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.3600 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.4000 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.4500 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.4800 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.4800 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.5000 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.5100 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.5200 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.5200 USD
ADR / (1.00 : 3.00)	Purchase	33 (99)	259.5300 USD
ADR / (1.00 : 3.00)	Purchase	67 (201)	259.5300 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.5300 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.5500 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.5500 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.5500 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.5600 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.5600 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.5600 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.5600 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.5600 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.5700 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.5700 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.5800 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.5900 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.6000 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.6000 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.6000 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.6000 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.6000 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.6000 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.6000 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.6100 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.6100 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.6100 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.6200 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.6200 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.6200 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.6200 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.6300 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.6400 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.6400 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.6500 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.6500 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.6500 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.6500 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.6500 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.6500 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.6500 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.6600 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.6600 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.6600 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.6700 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.6700 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.6800 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.6800 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.7000 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.7000 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.7200 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.7200 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.7400 USD
ADR / (1.00 : 3.00)	Purchase	96 (288)	259.7600 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.7700 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.7800 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.7800 USD
ADR / (1.00 : 3.00)	Purchase	19 (57)	259.7900 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.7900 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.7900 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.7900 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.8000 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.8000 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.8200 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.8300 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.8300 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.8300 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.8300 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.8300 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.8400 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.8400 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.8400 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.8400 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.8500 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.8500 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.8500 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.8500 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.8600 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.8600 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.8600 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.8600 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.8600 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.8600 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.8600 USD
ADR / (1.00 : 3.00)	Purchase	20 (60)	259.8700 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.8700 USD
ADR / (1.00 : 3.00)	Purchase	80 (240)	259.8800 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.8800 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.8800 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.8800 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.8800 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.8900 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.9000 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.9000 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.9000 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.9000 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.9100 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.9100 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.9200 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.9200 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.9200 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.9300 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.9500 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.9500 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.9600 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.9700 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.9800 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	259.9800 USD
ADR / (1.00 : 3.00)	Purchase	83 (249)	260.0000 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	260.0000 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	260.0000 USD
ADR / (1.00 : 3.00)	Purchase	17 (51)	260.0000 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	260.0000 USD
ADR / (1.00 : 3.00)	Purchase	49 (147)	260.0000 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	260.0100 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	260.0900 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	260.1000 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	260.1100 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	260.2600 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	260.2600 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	260.2600 USD
ADR / (1.00 : 3.00)	Purchase	200 (600)	260.2600 USD
ADR / (1.00 : 3.00)	Purchase	28 (84)	260.2600 USD
ADR / (1.00 : 3.00)	Purchase	500 (1,500)	260.2600 USD
ADR / (1.00 : 3.00)	Purchase	50 (150)	260.2600 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	260.2600 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	260.2600 USD
ADR / (1.00 : 3.00)	Purchase	72 (216)	260.2600 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	260.2600 USD
ADR / (1.00 : 3.00)	Purchase	50 (150)	260.2600 USD
ADR / (1.00 : 3.00)	Purchase	200 (600)	260.3400 USD
ADR / (1.00 : 3.00)	Purchase	97 (291)	260.3700 USD
ADR / (1.00 : 3.00)	Purchase	57 (171)	260.3800 USD
ADR / (1.00 : 3.00)	Purchase	52 (156)	260.3800 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	260.3800 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	260.3800 USD
ADR / (1.00 : 3.00)	Purchase	448 (1,344)	260.3800 USD
ADR / (1.00 : 3.00)	Purchase	52 (156)	260.3800 USD
ADR / (1.00 : 3.00)	Purchase	48 (144)	260.3800 USD
ADR / (1.00 : 3.00)	Purchase	52 (156)	260.3800 USD
ADR / (1.00 : 3.00)	Purchase	200 (600)	260.3800 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	260.3800 USD
ADR / (1.00 : 3.00)	Purchase	200 (600)	260.3800 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	260.3900 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	260.3900 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	260.4000 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	260.4000 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	260.4000 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	260.4000 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	260.4000 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	260.4000 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	260.4000 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	260.4000 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	260.4000 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	260.4000 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	260.4000 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	260.4000 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	260.4000 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	260.4000 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	260.4000 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	260.4000 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	260.4000 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	260.4000 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	260.4000 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	260.4000 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	260.4000 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	260.4000 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	260.4000 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	260.4000 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	260.4000 USD
ADR / (1.00 : 3.00)	Purchase	200 (600)	260.4000 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	260.4400 USD
ADR / (1.00 : 3.00)	Purchase	9 (27)	260.5000 USD
ADR / (1.00 : 3.00)	Purchase	22 (66)	260.5000 USD
ADR / (1.00 : 3.00)	Purchase	28 (84)	260.5000 USD
ADR / (1.00 : 3.00)	Purchase	194 (582)	260.5000 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	260.5000 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	260.5000 USD
ADR / (1.00 : 3.00)	Purchase	10 (30)	260.5000 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	260.5000 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	260.5000 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	260.5000 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	260.5000 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	260.5000 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	260.5000 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	260.5000 USD
ADR / (1.00 : 3.00)	Purchase	133 (399)	260.5000 USD
ADR / (1.00 : 3.00)	Purchase	50 (150)	260.5000 USD
ADR / (1.00 : 3.00)	Purchase	9 (27)	260.5000 USD
ADR / (1.00 : 3.00)	Purchase	22 (66)	260.5000 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	260.5000 USD
ADR / (1.00 : 3.00)	Purchase	168 (504)	260.5000 USD
ADR / (1.00 : 3.00)	Purchase	49 (147)	260.5000 USD
ADR / (1.00 : 3.00)	Purchase	200 (600)	260.5600 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	260.5600 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	260.5600 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	260.5600 USD
ADR / (1.00 : 3.00)	Purchase	300 (900)	260.5600 USD
ADR / (1.00 : 3.00)	Purchase	400 (1,200)	260.5600 USD
ADR / (1.00 : 3.00)	Purchase	22 (66)	260.5600 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	260.5600 USD
ADR / (1.00 : 3.00)	Purchase	178 (534)	260.5600 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	260.5700 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	260.7900 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	260.8200 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	260.8800 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	260.9050 USD
ADR / (1.00 : 3.00)	Purchase	100 (300)	261.0000 USD

Class of relevant security	Purchases/sales	Total number of securities
ADR / (1.00 : 3.00)	Purchases	25,000 (75,000)

(b) Derivatives transactions (other than options)

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

(i) Writing, selling, purchasing or varying

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

(ii) Exercising

Class of relevant security

Product description

e.g. call option

Number of securities

Exercise price per unit

(d) Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

The currency of all prices and other monetary amounts should be stated.

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

If there are no such agreements, arrangements or understandings, state "none"

NONE

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

NONE

Is a Supplemental Form 8 (Open Positions) attached?

YES

Date of disclosure:	01 October 2014
Contact name:	Aadithya Rao and Yiannis Bardis
Telephone number:	+44(20) 7051 9046 / +44(20) 7774 7107

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel's website atwww.thetakeoverpanel.org.uk.

SUPPLEMENTAL FORM 8(OPEN POSITIONS)

DETAILS OF OPEN OPTION AND DERIVATIVE POSITIONS, AGREEMENT TO

PURCHASE OR SELL ETC.

Note 5(i) on Rule 8 of the Takeover Code (the "Code")

1. KEY INFORMATION

Identity of the person whose open positions are being disclosed:	(GS) GOLDMAN, SACHS & CO.
Name of offeror/offeree in relation to whose relevant securities disclosure relates:	SHIRE PLC

2. OPTIONS AND DERIVATIVES

Class of relevant security	Product description e.g. call option	Written or purchased	Number of securities to which option or derivative relates	Exercise price per unit	Type e.g. American, European etc.	Expiry date
5p ordinary	Swap	Sold	198	0.0000	N/A	17/09/2015
5p ordinary	Swap	Sold	25,947	0.0000	N/A	17/09/2015
5p ordinary	Swap	Sold	72,603	0.0000	N/A	17/09/2015
5p ordinary	Swap	Sold	85,572	0.0000	N/A	17/09/2015

3. AGREEMENTS TO PURCHASE OR SELL

Full details should be given so that the nature of the interest or position can be fully understood:

It is not necessary to provide details on a Supplement form (Open Positions) with regard to contracts for differences ("CFD") or spread bets

The currency of all pieces and other monetary amounts should be stated.

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

This information is provided by RNS

The company news service from the London Stock Exchange

ENDFEOMBBTTMBMMBFI

distributed by

S&P 500 : Dealmakers brace for slowdown after third-strongest M&A year	18-12-21	RE
Asia M&A clocks second best on record, strength to persist despite trade troubles	18-12-20	RE
British shares falter as Fed, oil play Scrooge	18-12-20	RE
FTSE : GSK pulls FTSE 100 out of three-day rut, focus on Fed	18-12-19	RE
FTSE : Oil slide and growth worries smother FTSE 100 while mid-caps bounce	18-12-18	RE
FTSE : down sharply as ASOS profit alert sparks wider retail selloff	18-12-17	RE
FTSE : Oil helps FTSE 100 end turbulent week firmer, but Brexit weighs	18-12-07	RE
FTSE : falls as growth angst spreads	18-12-05	RE
Growth and trade nerves grind European shares down to two-week low	18-12-05	RE
Takeda Pharmaceutical : clears key hurdle as investors back $59 billion Shire deal	18-12-05	RE
Takeda Pharmaceutical : investors back $59 billion Shire deal, but wary of debt load	18-12-05	RE
Takeda Pharmaceutical : EU approves Takeda buying Shire, on divestment condition	18-11-21	RE
Takeda Pharmaceutical : Investor advisory firms back Takeda's $62 billion deal for Shire	18-11-21	RE
Takeda Pharmaceutical : Shire takeover to bring $963 million fee bonanza	18-11-12	RE
FTSE : outperforms European peers as Brexit angst sinks sterling	18-11-12	RE
Takeda Pharmaceutical : sets vote date, aims to close $62 billion Shire deal January 8	18-11-12	RE
Takeda Pharmaceutical : sets vote date, aims to close $62 billion Shire deal on January 8	18-11-12	RE
Exclusive: Takeda to win EU approval for $62 billion Shire deal - sources	18-11-09	RE
Exclusive: Takeda to win EU approval for $62 billion Shire deal - sources	18-11-09	RE
Takeda Pharmaceutical : CEO confident of investor backing for $62 billion Shire deal	18-11-05	RE
Takeda Pharmaceutical : hikes annual profit outlook by a third after second quarter profit jump	18-10-31	RE
Takeda Pharmaceutical : proposes sale of Shire drug to gain European approval	18-10-29	RE
Takeda Pharmaceutical : gets Japanese approval for $62 billion Shire purchase	18-10-18	RE
Bayer : Beset by copies, Roche gets sales boost from China	18-10-17	RE
FTSE : shrugs off Brexit impasse while Convatec and Superdry sink	18-10-15	RE

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+30.38%	695B
NOVO NORDISK A/S	+26.51%	568B
JOHNSON & JOHNSON	-4.36%	361B
MERCK & CO., INC.	+19.30%	330B
ABBVIE INC.	+3.73%	283B
ASTRAZENECA PLC	+16.70%	239B
NOVARTIS AG	+8.78%	204B
ROCHE HOLDING AG	-7.93%	198B
AMGEN INC.	+7.68%	168B

Shire

Equities

JE00B2QKY057

Pharmaceuticals

Shire : Form 8.5 (EPT/NON-RI)

Latest news about Shire

Chart Shire

Company Profile

Sector Other Pharmaceuticals